Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and …
D Gilligan, M Nicolson, I Smith, H Groen, O Dalesio… - The Lancet, 2007 - thelancet.com
Background Although surgery offers the best chance of cure for patients with non-small cell
lung cancer (NSCLC), the overall 5-year survival rate is modest, and improvements are …
lung cancer (NSCLC), the overall 5-year survival rate is modest, and improvements are …
[HTML][HTML] Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases …
P Mulvenna, M Nankivell, R Barton, C Faivre-Finn… - The Lancet, 2016 - thelancet.com
Background Whole brain radiotherapy (WBRT) and dexamethasone are widely used to treat
brain metastases from non-small cell lung cancer (NSCLC), although there have been no …
brain metastases from non-small cell lung cancer (NSCLC), although there have been no …
[HTML][HTML] Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
MF Muers, RJ Stephens, P Fisher, L Darlison… - The Lancet, 2008 - thelancet.com
Background Malignant pleural mesothelioma is almost always fatal, and few treatment
options are available. Although active symptom control (ASC) has been recommended for …
options are available. Although active symptom control (ASC) has been recommended for …
[HTML][HTML] Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two …
Background Men with high-risk non-metastatic prostate cancer are treated with androgen-
deprivation therapy (ADT) for 3 years, often combined with radiotherapy. We analysed new …
deprivation therapy (ADT) for 3 years, often combined with radiotherapy. We analysed new …
[HTML][HTML] Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer …
H Wasan, AM Meade, R Adams, R Wilson… - The Lancet …, 2014 - thelancet.com
Background Advanced colorectal cancer is treated with a combination of cytotoxic drugs and
targeted treatments. However, how best to minimise the time spent taking cytotoxic drugs …
targeted treatments. However, how best to minimise the time spent taking cytotoxic drugs …
Enhancing involvement of people with multiple sclerosis in clinical trial design
E Gray, A Amjad, J Robertson… - Multiple Sclerosis …, 2023 - journals.sagepub.com
Background: Although often overlooked, patient and public involvement (PPI) is vital when
considering the design and delivery of complex and adaptive clinical trial designs for chronic …
considering the design and delivery of complex and adaptive clinical trial designs for chronic …
[HTML][HTML] Quality of life in men with prostate cancer randomly allocated to receive docetaxel or abiraterone in the STAMPEDE trial
HL Rush, L Murphy, AK Morgans… - Journal of clinical …, 2022 - ncbi.nlm.nih.gov
Purpose Docetaxel and abiraterone acetate plus prednisone or prednisolone (AAP) both
improve survival when commenced alongside standard of care (SOC) androgen deprivation …
improve survival when commenced alongside standard of care (SOC) androgen deprivation …
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476 …
Abiraterone acetate plus prednisolone (AAP) previously demonstrated improved survival in
STAMPEDE, a multiarm, multistage platform trial in men starting long‐term hormone therapy …
STAMPEDE, a multiarm, multistage platform trial in men starting long‐term hormone therapy …
[HTML][HTML] Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final …
Background Abiraterone acetate plus prednisolone (herein referred to as abiraterone) or
enzalutamide added at the start of androgen deprivation therapy improves outcomes for …
enzalutamide added at the start of androgen deprivation therapy improves outcomes for …
[HTML][HTML] This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols
F Schiavone, R Bathia, K Letchemanan, L Masters… - Trials, 2019 - Springer
Background There are limited research and literature on the trial management challenges
encountered in running adaptive platform trials. This trial design allows both (1) the …
encountered in running adaptive platform trials. This trial design allows both (1) the …